History
What we have achieved.
Our tradition of innovations is long. We have been inventing therapeutic solutions for the unmet needs of patients and healthcare providers for more than 110 years, always following the principle of our founder Friedrich Merz: “Do it differently than the others.”
In order to meet patients’ needs even better and to reach even more people by driving responsible growth, Merz Therapeutics, part of the Merz Group, has been operating as an individual business since 2020.
At a glance
History of therapeutic innovations
Launch of Contractubex®
Prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammat ...
Launch of Contractubex®
Prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammatory, anti-redness, reducing swelling, pain and irritation
Launch of Hepa-Merz®
For the treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and it ...
Launch of Hepa-Merz®
For the treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and its complications (hepatic encephalopathy)
Launch of PK-Merz®
For the treatment of symptoms of Parkinson‘s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrap ...
Launch of PK-Merz®
For the treatment of symptoms of Parkinson‘s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrapyramidal symptoms such as early dyskinesia, akathisia, and parkinsonoid syndrome
Launch of Pantogar®
Oral hair and nail therapeutic agent for the treatment of various forms of diffuse hair loss and improvement in hair ...
Launch of Pantogar®
Oral hair and nail therapeutic agent for the treatment of various forms of diffuse hair loss and improvement in hair growth, hair damaged by sunlight and UV radiation and nail growth disorders
Introduction of a new formula of Memantine
First active compound worldwide for the treatment of moderate to severe Alzheimer’s disease
Launch of a new formula of botulinum neurotoxin type A
German approval for the treatment of blepharospasm and cervical dystonia in adults
Botulinum neurotoxin type A
EU approval for the treatment of post-stroke upper limb spasticity in adults
Botulinum neurotoxin type A
US approval for the treatment of adults with cervical dystonia and blepharospasm (pre-treated with onabotulinumtoxina ...
Botulinum neurotoxin type A
US approval for the treatment of adults with cervical dystonia and blepharospasm (pre-treated with onabotulinumtoxina)
Cuvposa®
FDA-approved treatment for the treatment of chronic severe drooling in pediatric patients with neurological condition ...
Cuvposa®
FDA-approved treatment for the treatment of chronic severe drooling in pediatric patients with neurological conditions, the only liquid formulation on the market, designed with the aim to deliver an individualized dose for patients
Launch of ProlarynTM gel and plus
Proven injectable implants indicated for the treatment of vocal fold insufficiency, providing both short-term and lon ...
Launch of ProlarynTM gel and plus
Proven injectable implants indicated for the treatment of vocal fold insufficiency, providing both short-term and long-term options for patients in a single portfolio
Botulinum neurotoxin type A
US approval for the treatment of adult patients with upper limb spasticity
Botulinum neurotoxin type A
US approval for the treatment of adults with chronic sialorrhea
Botulinum neurotoxin type A
- EU approval for the treatment of chronic sialorrhea in adults
- US approval for first-li ...
Botulinum neurotoxin type A
- EU approval for the treatment of chronic sialorrhea in adults
- US approval for first-line treatment of adults with blepharospasm
- EU approval for the symptomatic treatment of hemifacial spasm in adults
Start of Merz Therapeutics as an own business
Start of Merz Therapeutics as a dedicated business within the Merz Group committed to serving the unmet needs of pati ...
Start of Merz Therapeutics as an own business
Start of Merz Therapeutics as a dedicated business within the Merz Group committed to serving the unmet needs of patients suffering from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life
Botulinum neurotoxin type A
- Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the ...
Botulinum neurotoxin type A
- Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the treatment of upper limb spasticity in adults
- US approval for the treatment of upper limb spasticity in pediatric patients age 2 to 17, excluding spasticity caused by cerebral palsy
- US approval for the treatment of chronic sialorrhea in patients age 2 and older. The first neurotoxin on the market to treat pediatric patients suffering from sialorrhea
Botulinum neurotoxin type A
- Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the ...
Botulinum neurotoxin type A
- Partner in Japan Teijin Pharma receives approval to market botulinum neurotoxin type A for the treatment of lower limb spasticity in adults
- EU approval for the symptomatic treatment of chronic sialorrhea due to neurological / neurodevelopmental disorders in children and adolescents age 2 to 17
- Merz and the Israeli start-up Vensica launch strategic partnership for the needleless treatment of overactive bladder delivering Botulinum neurotoxin type A to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter